Novo Nordisk obtains EU positive opinion for diabetes drug
Victoza is the brand name for liraglutide, the first once-daily human glucagon-like peptide-1 (GLP-1) analog developed for the treatment of type 2 diabetes, the company said. The positive
Alkermes has received orphan drug designations (ODD) from both the US Food and Drug Administration (FDA) and the European Commission (EC) for alixorexton, its investigational oral orexin 2 receptor (OX2R) agonist to treat idiopathic hypersomnia (IH) and narcolepsy.